230 related articles for article (PubMed ID: 36334220)
1. How Have Targeted Agents Changed the Treatment Landscape for Elderly Patients with CLL?
Rhodes JM; Barrientos JC; Rai KR
Curr Oncol Rep; 2022 Dec; 24(12):1705-1713. PubMed ID: 36334220
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.
Shadman M
JAMA; 2023 Mar; 329(11):918-932. PubMed ID: 36943212
[TBL] [Abstract][Full Text] [Related]
3. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
Cramer P; von Tresckow J; Eichhorst B; Hallek M
Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
[TBL] [Abstract][Full Text] [Related]
4. Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis.
Davids MS; Waweru C; Le Nouveau P; Padhiar A; Singh G; Abhyankar S; Leblond V
Clin Ther; 2020 Oct; 42(10):1955-1974.e15. PubMed ID: 33032842
[TBL] [Abstract][Full Text] [Related]
5. The fading star of obinutuzumab-chlorambucil regimen in patients with comorbidities with chronic lymphocytic leukemia - are we ready for chemo-free immunotherapy approach?
Milunović V; Mišura Jakobac K; Mandac Rogulj I; Martinović M; Radić-Krišto D; Ostojić Kolonić S
Expert Rev Hematol; 2020 Jul; 13(7):771-779. PubMed ID: 32579408
[TBL] [Abstract][Full Text] [Related]
6. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.
Wendtner CM; Gregor M
Leuk Lymphoma; 2018 Feb; 59(2):300-310. PubMed ID: 28565930
[TBL] [Abstract][Full Text] [Related]
7. Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape.
Iovino L; Shadman M
Curr Treat Options Oncol; 2020 Mar; 21(4):24. PubMed ID: 32170458
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope.
Goede V; Hallek M
Drugs Aging; 2015 Nov; 32(11):877-86. PubMed ID: 26446155
[TBL] [Abstract][Full Text] [Related]
9. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
Mato AR; Hill BT; Lamanna N; Barr PM; Ujjani CS; Brander DM; Howlett C; Skarbnik AP; Cheson BD; Zent CS; Pu JJ; Kiselev P; Foon K; Lenhart J; Henick Bachow S; Winter AM; Cruz AL; Claxton DF; Goy A; Daniel C; Isaac K; Kennard KH; Timlin C; Fanning M; Gashonia L; Yacur M; Svoboda J; Schuster SJ; Nabhan C
Ann Oncol; 2017 May; 28(5):1050-1056. PubMed ID: 28453705
[TBL] [Abstract][Full Text] [Related]
10. Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia.
Egyed M; Lueff S; Borbely J; Illes A
Future Oncol; 2022 Mar; 18(7):755-769. PubMed ID: 35139644
[TBL] [Abstract][Full Text] [Related]
11. First line therapy of CLL.
Hallek M
Hematol Oncol; 2023 Jun; 41 Suppl 1():129-135. PubMed ID: 37294974
[TBL] [Abstract][Full Text] [Related]
12. Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective.
Owen C; Assouline S; Kuruvilla J; Uchida C; Bellingham C; Sehn L
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):627-634.e5. PubMed ID: 26416145
[TBL] [Abstract][Full Text] [Related]
13. Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia.
Chung C; Lee R
Pharmacotherapy; 2014 Dec; 34(12):1298-316. PubMed ID: 25355689
[TBL] [Abstract][Full Text] [Related]
14. Progress in the treatment of elderly/unfit chronic lymphocytic leukemia patients: results of the German CLL-11 trial.
Molica S
Expert Rev Anticancer Ther; 2015 Jan; 15(1):9-15. PubMed ID: 25479582
[TBL] [Abstract][Full Text] [Related]
15. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
Fischer K; Al-Sawaf O; Bahlo J; Fink AM; Tandon M; Dixon M; Robrecht S; Warburton S; Humphrey K; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Boettcher S; Tausch E; Humerickhouse R; Eichhorst B; Wendtner CM; Langerak AW; Kreuzer KA; Ritgen M; Goede V; Stilgenbauer S; Mobasher M; Hallek M
N Engl J Med; 2019 Jun; 380(23):2225-2236. PubMed ID: 31166681
[TBL] [Abstract][Full Text] [Related]
16. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
Hallek M
Am J Hematol; 2017 Sep; 92(9):946-965. PubMed ID: 28782884
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
Jain N; O'Brien S
Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
[TBL] [Abstract][Full Text] [Related]
18. BTK Inhibitors in Chronic Lymphocytic Leukemia.
Gaballa S; Pinilla-Ibarz J
Curr Hematol Malig Rep; 2021 Oct; 16(5):422-432. PubMed ID: 34599723
[TBL] [Abstract][Full Text] [Related]
19. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
Hallek M
Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target.
Morabito F; Gentile M; Seymour JF; Polliack A
Leuk Lymphoma; 2015; 56(12):3250-6. PubMed ID: 26062943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
